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ABSTRACT
Purpose: Little is known on the beliefs, perceptions and practices of hypertension specialists in
addressing non-adherence to therapy. Therefore, a survey was undertaken amongst healthcare
professionals (HCPs) managing hypertension in the European Society of Hypertension (ESH)
Centres of Excellence.
Materials and methods: Cross-sectional data were obtained between December 2020 and April
2021 using an online anonymous structured questionnaire including 26 questions/136 items,
that was sent to all ESH Excellence centres.
Results: Overall 67 from 187 centres (37.3%) responded and 200 HCPs from 30 countries
answered the questionnaire. Participants (60% men) were mainly physicians (91%) and nurses
(8%) from University hospitals (77%). Among physicians, 83% had >10 years professional experi-
ence. Average time dedicated to discuss medications was 1-5 min in 48% and 6-10 min in 29%
of cases. Interviews with patients about adherence were the most frequently used assessment
method. Chemical detection of medications in urine was available in 36% of centres. One third
of physicians involved their patients regularly in treatment decisions. The most frequent meth-
ods to improve adherence included simplification of medication therapy, more frequent visits,
and home blood pressure monitoring. Conclusions: The level of implementation of tools to
detect and improve adherence in hypertension management in ESH excellence centres is low.
Structured educational activities and access to the newest objective measures to detect non-
adherence might improve these deficits.
Conclusions: The level of implementation of tools to detect and improve adherence in hyper-
tension management by HCPs in ESH excellence centres is low. Structured educational activities
focussing on adherence management and access to the newest objective measures to detect
non-adherence might improve these deficits.
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The European Society of Cardiology and the
European Society of Hypertension 2018 recommenda-
tions on the management of hypertension in adults
state that three important factors contribute to the
poor control of blood pressure (BP) in hypertension
[1]. These factors are low patients’ adherence to non-
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pharmacological as well as to pharmacological treat-
ments, therapeutic/physician inertia and deficiencies
of healthcare systems in their approach to chronic
diseases [1]. A partial or complete non-adherence to
prescribed medications is very common in chronic
‘silent’ diseases, such as hypertension and dyslipide-
mia or diabetes [2]. In chronic diseases such as hyper-
tension, the causes and implications of non-adherence
are multidimensional and complex [3]. Thus, poor
adherence not only limits a physician’s ability to
achieve optimal BP control but also significantly
impairs the capacity to reduce the patients’ cardiovas-
cular risk [4] and the occurrence of severe clinical
outcomes such as stroke, heart failure, coronary artery
disease or chronic kidney diseases [3,5–7].
Since the last few decades, great efforts have been
dedicated to the detection of patients who are poorly
adherent to their antihypertensive medications [3,8,9].
This was important because recognition of partial or
complete non-adherence is very difficult [10] and rep-
resents the crucial first step of any intervention on
medication adherence [8]. Several qualitative studies
have examined patients’ perspectives regarding their
beliefs and attitudes towards the need of taking medi-
cations to treat their hypertension [11]. One large
European survey investigated how healthcare profes-
sionals (HCPs) such as physicians, nurses and phar-
macists supported patients with taking medicines and
evaluated their perceptions about the effectiveness of
those actions [12]. However, little is known about the
beliefs, perceptions and practices of hypertension spe-
cialists in addressing non-adherence to therapy.
Therefore, this study aimed to understand, through a
survey, the beliefs and behaviour of healthcare profes-
sionals in managing non-adherence in hypertension
amongst European Centres of Excellence of the
European Society of Hypertension (ESH).
Methods
This survey focussed on the perception of initiation,
adherence and persistence to antihypertensive medica-
tions of HCPs. In addition, the survey evaluated
HCPs’ beliefs and behaviours regarding adherence
including the choice of approaches to assess medica-
tion adherence and interventions to improve adher-
ence to medication therapy. A previously published
questionnaire was slightly adapted (Supplementary
Appendix 1) and used with the permission of the
authors [13]. This questionnaire has been developed
and previously used in the European Ascertaining
Barriers for Compliance (ABC) project (http://www.
ABCproject.eu) and is based on a combination of
published but unvalidated scales measuring aspects of
HCPs behaviours and recommendations for clinical
practice from published adherence guidelines [14].
The questionnaire was modified for the present study
to include questions on new techniques such as the
chemical detection of antihypertensive medications. It
contains 26 questions and 136 items. The first seven
questions on the characteristics of the participants
were mandatory in order for the questionnaire to
be validated.
This cross-sectional multinational online observa-
tional survey was addressed to all the designated leads
or contact persons of the Centres of Excellence of the
European Society of Hypertension (n¼ 187) using the
SoGo Survey platform. (www.sogosurvey.com).
Thereafter, all the leads were requested to distribute
the survey internally to the members of their
Excellence Centre, for example, to other HCPs
involved in hypertension management in their centre.
All participants could complete the survey only once.
In case of non-response, one reminder e-mail was
sent. The study was conducted between 1 December
2020 and 1 April 2021. Approval was waived by the
ethics committee considering the fact that answering
the questionnaire was free and represented impli-
cit consent.
Statistics
Descriptive analyses of the data were undertaken to
show the distribution of the percentage of answers in
each answer category for every item. Missing data
were excluded from the analysis. Data were analysed
according to sex and years of professional experience.
Results
Overall 67 of the 187 centres responded resulting in a
response rate of 37.3%. A total of 205 HCPs partici-
pated in the survey from the 67 centres. From these,
5 responses had to be excluded because mandatory
questions were not completed, thus providing an
average of 3.1 responses per centre. Results from 200
questionnaires from 30 countries were available for
further analyses. As shown in Table 1, the majority of
participants were males (60%). The respondents were
mainly physicians (91%) and from University hospi-
tals (77%), while 8% were nurses, only a few were
biologists working in laboratories and no pharmacist
participated. Participating HPCs were largely treating
adult (99%) patients with hypertension. The large
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majority of participants (83%) had a professional
experience of more than 10 years.
Table 2 shows the participants’ perception on initi-
ation of therapy, adherence and persistence of
patients treated for hypertension in their countries
and their centres. When evaluating the entire popula-
tion of their country, 42% of participants estimated
that 0–15% of patients did not initiate their antihy-
pertensive therapy and 44% of participants suggested
that this number ranges between 16 and 35%.
Regarding their perception of adherence and persist-
ence, half of the participants believed that 36–65% of
patients were adherent to therapy and persistent on
therapy at 1 year. One-quarter of the answers sug-
gested that adherence and persistence range between
66 and 85%. Interestingly, when assessing their own
patients, participants were more positive with 66% of
participants considering that less than 15% of their
patients do not initiate therapy and 59% of partici-
pants estimating that adherence and one-year persist-
ence ranges between 65 and 100%.
Figure 1 shows the time spent talking with patients
about their use of medications according to sex. The
majority of participants indicate that they spent
between 1 and 5min and about one-third of them
spent 6–10min discussing medication therapy with
their patients. Females tend to spend a bit more time
talking with patients but one must take into account
that 20% of participating females were nurses, who
dedicated more time with patients in their interviews.
Indeed 6.5% of physicians answered that they spend
more than 15min discussing the use of medication
whereas this percentage was 31.5% for nurses. When
Table 1. Demographic characteristics of the participants.
Characteristic
Gender, n (%) Men, 120 (60) Women, 80(40)
Profession Physicians, 182 (91%) Nurses, 16 (8%) Others, 2 (1%)
Hypertension
specialists, n (%)a
Yes, 212 (61%) No, 79 (39%)
Years since qualifying,
n (%)





























Greece (27) UK (22) France (23) Italy (19) Brazil (15)
Poland (13) Switzerland (11) Spain (9) Belgium (8) Estonia (8)
aAccording to the ESH certification; bSome physicians had more than one affiliation or specialty.
Table 2. Healthcare professionals’ perception on initiation of therapy, adherence and persistence of patients treated for hyper-
tension in their country and in their own centre.
Perception 0–15% 16–35% 36–65% 66–85% 86–100%
National specific perceptions
Patients who do not initiate their medications (n¼ 198) (%) 83 (42%) 87 (44%) 26 (13%) 2 (1%) 0%
Patients who do take their medications as prescribed (n¼ 197) (%) 3 (2%) 36 (18%) 101 (51%) 52 (26%) 5 (3%)
Patients who persist with their medications at 1 year (n¼ 198) (%) 0 (0%) 37 (19%) 99 (50%) 55 (28%) 7 (4%)
Center specific perceptions
Patients who do not initiate their medications (n¼ 196) (%) 129 (66%) 57 (29%) 6 (3%) 2 (1%) 2 (1%)
Patients who do take their medications as prescribed (n¼ 196) (%) 16 (8%) 24 (12%) 42 (22%) 87 (45%) 27 (14%)
Patients who persist with their medications at 1 year (n¼ 195) (%) 6 (3%) 13 (7%) 61 (31%) 86 (44%) 29 (15%)
No difference between males and females.
Figure 1. Time spent talking with patients about their use of
medications.
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considering physicians only, we found no difference
between men and women.
Table 3 shows that more than 90% of participants
agreed or strongly agreed that patients’ beliefs and
concerns about antihypertensive medications have an
impact on adherence and persistence. More than 95%
of HCPs also agree/strongly agree that adherence can
be improved, but the majority (82.8%) agreed that
one single intervention cannot resolve all adherence
issues. The participants’ opinion on whether non-
adherence is intentional or not appears to be more
divided. Further, 80.1% of HCPs agreed with the fact
that patients have the right to refuse or to stop their
medications provided they are correctly informed on
the risks. Interestingly, more than 60% of participants
consider that non-adherence is difficult to recognise
(answers to the question: moderately and very much).
The survey included several questions on the meth-
ods used to assess adherence in patients with hyper-
tension. It is evident from Table 4, that asking
patients specific questions on the way they handle
their medications is the most common approach.
Also, interactions with the family, friends or other
HCPs to assess non-adherence are common.
Interestingly, most objective approaches such as using
questionnaires, electronic monitors, dedicated Apps,
pill count tools, and chemical detection of medica-
tions in urine or blood and directly observed therapy
are either not used or used only occasionally.
Pharmacy data appear to be used frequently by about
20% of participants and from time to time by 35%
of them.
Methods and approaches used by participants to
improve medication adherence are shown in Table 5.








Patients’ beliefs affect their adherence (n¼ 190) 3 (2%) 3 (2%) 9 (5%) 56 (29%) 119 (62%)
Patients concerns about medication affect their adherence (n¼ 192) 1 (0.5%) 3 (1.5%) 14 (7%) 78 (41%) 96 (50%)
Most non-adherence is intentional (n¼ 191) 0 (0%) 44 (23%) 53 (28%) 69 (36%) 25 (13%)
Most non-adherence is unintentional (n¼ 189) 14 (7%) 60 (32%) 56 (30%) 52 (27%) 7 (4%)
It is possible to improve adherence (n¼ 189) 1 (0.5%) 2 (1.0%) 4 (2%) 83 (44%) 99 (52.5%)
There is not one specific intervention for improving adherence
suitable for everyone (n¼ 190)
7 (4%) 11 (5.5%) 13 (7%) 79 (41.5%) 80 (42%)
Patients have the right to refuse or to stop taking their medication
provided they are informed (n¼ 191)
6 (3%) 10 (5%) 21 (11%) 94 (49.5%) 60 (31.5%)
Table 4. Methods used to assess adherence in patients with hypertension.
Method used Never Occasionally Sometimes Frequently Always
Ask questions on missed doses (n¼ 194) 2 (1%) 10 (5%) 21 (11%) 66 (34%) 95 (49%)
Ask questions on reduced doses (n¼ 192) 7 (4%) 20 (10%) 31 (16%) 46 (24%) 88 (46%)
Ask questions on changes of medication regimen (n¼ 194) 2 (1%) 7 (4%) 21 (11%) 51 (26%) 113 (58%)
Speak to family, friends or healthcare providers (n¼ 191) 10 (5.5%) 58 (30%) 55 (29%) 46 (24%) 22 (11.5%)
Use of questionnaires (n¼ 190) 96 (50.5%) 40 (21%) 27 (14.2%) 17 (9%) 10 (5.3%)
Take blood or urine to measure medications (n¼ 189) 89 (47%) 43 (23%) 20 (10.5%) 27 (14%) 10 (5.5%)
Use electronic monitors (n¼ 191) 124 (65%) 22 (11%) 11 (6%) 24 (13%) 10 (5%)
Use pill counts (n¼ 189) 113 (60%) 35 (18.5%) 22 (11.5%) 14 (7%) 5 (3%)
Use direct observed treatment (DOT) (n¼ 188) 81 (43%) 53 (28%) 30 (16%) 19 (10%) 5 (3%)
Use pharmacy data (n¼ 189) 83 (44%) 39 (20.5%) 28 (15%) 27 (14%) 12 (6.5%)
Use Apps data provided by patients (n¼ 190) 121 (64%) 44 (23%) 15 (8%) 8 (4%) 2 (1%)
Table 5. Methods and interventions used to improve medication adherence in hypertensive patients.
Method used Never Occasionally Sometimes Frequently Always
I reduce the administration frequency (n¼ 179) 1 (0.5%) 2 (1%) 21 (11.5%) 74 (41.5%) 81 (45.5%)
I use single pill combinations (n¼ 179) 4 (2%) 5 (3%) 18 (10%) 69 (38.5%) 83 (46.5%)
I stop unnecessary medications (n¼ 178) 2 (1%) 3 (2%) 11 (6%) 61 (34%) 101 (57%)
I use medication in packaging that patients will find easy to use (n¼ 169) 25 (15%) 30 (18%) 41 (24%) 43 (25%) 30 (18%)
I recommend to associate medications intake with routine activities (n¼ 182) 3 (2%) 14 (8%) 34 (19%) 72 (39%) 59 (32%)
I recommend the use of reminders (pagers, mobile phone, watches) (n¼ 183) 21 (11.5%) 22 (12%) 63 (34.5%) 54 (29.5%) 23 (12.5%)
I provide patients with written information (paper) on their medications (n¼ 188) 48 (25.5%) 25 (13.3%) 31 (16.5%) 44 (23.5%) 40 (21.2%)
I recommend medication dispensers (n¼ 181) 23 (12.5%) 32 (18%) 46 (25.5%) 59 (32.5%) 21 (11.5%)
I recommend the use of medication charts or diaries (n¼ 180) 36 (20%) 33(18%) 53 (30%) 33 (18%) 25 (14%)
I encourage involvement of family, friends or carers to support adherence (n¼ 186) 9 (5%) 33 (18%) 64 (34%) 45 (24%) 35 (19%)
I recommend the support of the patient’s pharmacist (n¼ 175) 57 (32.5%) 38 (22%) 48 (27.5%) 20 (11%) 12 (7%)
I recommend the support of a nurse (n¼ 178) 36 (20%) 43 (24%) 35 (20%) 41 (23%) 23 (13%)
I encourage self- monitoring of blood pressure (n¼ 187) 1 (0.5%) 3 (1,5%) 6 (3%) 58 (31%) 119 (64%)
I schedule more frequent appointments (n¼ 183) 5 (3%) 6 (3%) 30 (16%) 73 (40%) 69 (38%)
The percentage of participants who answered “not applicable” to the various questions was 2–9%.
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HCPs appear to work essentially on simplifying treat-
ment schemes, associating medication intake with
routine activities, using medication dispensers, pro-
viding written information, recommending home BP
monitoring and increasing the frequency of medical
consultations. The involvement of family members
and nurses is common but collaboration with phar-
macists is limited.
Among the barriers encountered by the partici-
pants to address adherence issues correctly and to
implement adherence enhancing interventions, the
most frequently mentioned are: the identification of
non-adherent patients, the short duration of consulta-
tions, the high workload, the lack of continuity of
antihypertensive care to support adherence, inad-
equate resources available in the healthcare system
(Supplemental Table 1). The lack of financial incen-
tives appears to be only a moderate barrier.
Figure 2 shows the participants’ behaviour in terms
of sharing treatment decisions with patients. Data
show that a substantial percentage of HCPs do not
ask their patients if they want to be involved in thera-
peutic decisions and admit having some difficulties
involving their patients in treatment decisions. In
accordance with these difficulties, 56% of participants
had never had any training on the management of
adherence during their medical or nursing education
and an adherence management program was lacking
in close to 60% of centres.
Analyses of the survey according to the number of
years of professional experience (> or <10 years of
clinical experience) demonstrated that healthcare pro-
viders with shorter experience are less confident in
their abilities to obtain a long-term adherence and
persistence and to involve patients in treatment deci-
sions. They tend to be more prone to using modern
approaches to support adherence such as phone appli-
cations or videos but the number of participants with
<10 years of experience is small; hence results are
non-conclusive. For all other aspects, there was no
difference between clinicians with short or long clin-
ical experience.
Discussion
Taken together, the main observations of this survey
are the following: firstly, HCPs estimated that the ini-
tiation, adherence and persistence to antihypertensive
medications are far from being ideal even among
their own patients. Secondly, HCPs from ESH
Centres of Excellence devote little time to discuss
antihypertensive medication therapies and patients are
infrequently involved in therapeutic decisions.
Thirdly, physicians/nurses admit that patients’ beliefs
have a great impact on adherence to medications and
that a ‘one size fits all’ approach to support adherence
does not exist. Fourthly, talking with patients about
their medicine use remains the most frequent method
to assess medication adherence and the use of other
techniques including chemical detection of medica-
tions or electronic monitoring to detect non-adherent
patients is still infrequent (<30%). Fifthly, simplifying
treatment schemes using single-pill combinations,
stopping unnecessary medications, combining medica-
tion intake with regular daily activities, more frequent
consultations, use of reminders, and home blood
pressure monitoring are the most commonly used
approaches to support long-term adherence. Lastly,
the majority of Centres of Excellence have no adher-
ence program and no specific training tools for
improving adherence. Yet, they recognise that non-
adherent patients are difficult to identify. In few
centres, physicians collaborate with nurses but the
collaboration with pharmacists is almost inexistent.
Over 50% believed that most non-adherence is inten-
tional, which also may influence other answers and
interventions considered most effective.
Figure 2. (a, b) Involvement of patients in treat-
ment decisions.
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To our knowledge, this is the first survey investi-
gating the beliefs and behaviours of treating patients
with hypertension in reference centres. The question-
naire that was used in this survey had been developed
by Clyne et al. [13] to examine the perceptions, beliefs
and behaviours of primary HCPs, for example, doc-
tors, pharmacists and nurses, about patient medica-
tion adherence in 10 European countries. Their first
publication reported the answers of 3196 healthcare
professionals comprising doctors (855), nurses (1047)
and pharmacists (1294) practicing in primary care
and community settings [12]. Our survey differs from
this initial report as it included almost exclusively
physicians (few nurses and no pharmacist) working in
secondary and tertiary care centres, mainly univer-
sities, and predominantly included those with a long
experience in the management of hypertension.
When asked about their perception of the extent of
patients’ non-adherence in terms of initiation of ther-
apy, adherence and persistence, participants indicate
that a substantial percentage of patients do not initi-
ate the prescribed therapy. The percentage of patients
with adherence and persistence >86% is low, for
example, <5% for hypertensive patients treated in the
community and 14% for their own patients.
Whether the differences reported between the com-
munity and reference centres are true or reflects a
healthcare professionals’ optimistic bias cannot be
ascertained. Indeed, primary care physicians treating
patients with chronic diseases have given similar
answers, with their own patients having a higher like-
lihood to be adherent and persistent [15,16].
Regarding the percentage of patients who do not initi-
ate their medications, the physicians’ perception is in
line with data indicating that primary non-adherence,
that is, not initiating a prescription, affects 24–28% of
patients with hypertension in the United States and is
frequent and of the same magnitude in almost all
patients with chronic diseases [17,18].
Hypertension is a silent disease needing life-long
therapy. Adaptations of prescriptions are frequent due
to either insufficient efficacy or to the development of
early or late side effects. In addition, barriers to medi-
cation adherence are multiple during the follow-up of
patients with hypertension [3]. Therefore, the likeli-
hood that patients become non-adherent to medica-
tions at one time or another is very high. The time
spent during consultations talking about antihyperten-
sive medications is an important component of the
long-term success of antihypertensive therapy. Indeed,
older studies have shown that consultations of longer
duration are associated with greater patient
satisfaction, increased health education/prevention
measures including more blood pressure measure-
ments, and no increase in prescriptions [19,20]. In
our survey, the self-reported time spent discussing
medication therapy ranged between 1 and 5min for
50% of participants and between 6 and 10min for
nearly one-third of participants (physiciansþnurses).
Only about one-third of all (n¼ 6) participating
nurses spent more than 15min discussing medication
treatments with their patients. One might think that
these durations are short considering the importance
of the issue. However, one should be cautious when
concluding because one cannot estimate what these
durations represented in terms of proportion of the
length of the entire consultation, as we did not find
any data on the length of hypertension consultations
in reference centres. Moreover, one could not make
any distinction between the initial and the follow-up
consultations, the former being usually of much lon-
ger duration than the latter. Nonetheless, it is interest-
ing to mention that the same distribution of time
spent discussing medication therapy was obtained in
the primary care survey including more than 3000
doctors, nurses, and pharmacists, respectively 54% for
1–5min and 25% for 6–10min [12]. In Europe, the
mean duration of primary care consultations is highly
variable ranging between 7.6 and 15min in 2002 with
large differences between countries [21] and a trend
to increase in recent years in some countries [22].
Hence, these figures would suggest that primary care
physicians dedicate little time in discussing medica-
tion therapies in patients with chronic diseases.
Whether this is also true in secondary care centres
would be important to confirm, as it might be a rele-
vant topic of action to improve medication adherence
in hypertension.
Recognition of non-adherent patients is a crucial
step in the long-term management of hypertension.
As expected, most participants perceived that identifi-
cation of non-adherent patients is not an easy task
and that they have only limited practical tools avail-
able to perform an effective and reliable detection of
non-adherent patients. Our assessment of the meth-
ods used to detect non-adherence in hypertensive
patients would support this observation. Indeed, ask-
ing patients about their medications duration the
interview and talking with family members or friends
remain the main approaches to get information on
how patients manage their antihypertensive medica-
tions on a day-to-day basis. Of course, discussing
with patients is essential in the doctor-patient rela-
tionship, but studies have demonstrated that
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interviewing patients with uncontrolled blood pres-
sure on adherence has low reliability [23]. Thus,
among the various methods available to identify non-
adherent patients, HCPs of ESH Centres of Excellence
continue to rely mainly on easily available, cheap but
poorly reliable methods. To our surprise, more reli-
able, but also more costly, methods such as chemical
detection of medication in blood or urine, electronic
monitoring or directly observed treatments are used
occasionally by less than 20% of participants. In this
respect, reference centres do not differ substantially
from general practitioners despite the fact that the
availability of reliable methods is usually greater in
reference centres. This might change in the future as
guidelines are being developed on the set up of some
methods such as chemical detection of medications in
urine or blood [24]. Thus, many reference centres are
now implementing this method of detection with full
knowledge of its advantages and limitations (punctual
estimation, limited information on duration of effect,
white coat adherence).
The interventions used by participants to improve
medication adherence in patients with hypertension
were very much in line with the latest 2018 ESC/ESH
recommendations [1]. Simplification of treatment
schemes using single-pill combinations, coupling
medication intake with routine activities, recommen-
dations to use home blood pressure monitoring or
pill organisers, proposing more frequent consultations
in case of apparent resistance to therapy are the most
frequently used interventions cited by participants.
Interestingly, answers regarding the involvement of
family members and nurses are heterogeneous
whereas collaborations with pharmacists are scarce.
This is rather surprising as more than 80% of partici-
pants answered that they had the possibility to collab-
orate with nurses and pharmacists in their
institutions. Several large studies have demonstrated
the clinical interest of a team-based collaboration with
nurses and pharmacists to improve blood pressure
control in hypertension [25–28]. In general, they have
shown that the likelihood of controlling blood pres-
sure was higher when a nurse/pharmacist was
involved in the management. The development of
team-based care programs in Centres of Excellence
might be another effective approach to improve and
support long-term medication adherence in patients
with hypertension, with a possible extension to other
chronic diseases [29].
Sharing decisions regarding their antihypertensive
treatments and empowering patients are now two
strategies strongly recommended by European
guidelines [1]. These approaches could facilitate long-
term adherence and lead to improved outcomes for
patients with hypertension and other chronic cardio-
vascular diseases [30]. Answers provided by doctors
participating in our survey suggest that a large per-
centage of them are still not using this approach
although the large majority of our participants had
more than ten years of clinical practice. In accordance
with these observations, more than 50% of partici-
pants have never had any training on how to conduct
an interview on adherence and do not have any
adherence program in their centre. This suggests that
there is a lot of room for improvement. ESH-based
educational programs dedicated to healthcare profes-
sionals could be developed in order to promote an
effective doctor-patient relation when addressing
medication adherence issues.
As with most surveys, our study has several limita-
tions. The first is the rather small sample size and,
despite the fact that 30 countries contributed to the
survey, analyses according to countries or regions
could not be performed. Secondly, the involvement of
nurses and pharmacists was small. Thirdly, the survey
concerns self-reports by HCPs of the interventions
they undertake towards managing and supporting
patients with medication adherence. However, we do
not have any objective data to confirm their percep-
tions. It would be of interest to complement this
study by a survey involving patients followed in the
same centres and to compare, for example, the time
dedicated to discussing medications as reported by
HCPs and patients. Such an approach was recently
used to analyse the quality of BP measurements in
dialysis centers [31]. Lastly, participants completing
our survey were free to participate. Thus, one cannot
exclude that this self-selected sample is affected by a
selection bias with participants who are more inter-
ested in medication adherence than the HCPs work-
ing in all reference centres and other workplaces
approaching hypertensive patients.
In conclusion, the present survey indicates that
HCPs (largely physicians and nurses) working in ESH
Centres of Excellence are well aware of the problems
associated with medication adherence in the thera-
peutic management of hypertension. However, their
answers demonstrate that there are major barriers to
the ability to detect non-adherence in clinical practice
and to implement effective methods to support
patients’ adherence. This survey also identifies several
aspects of the management of hypertension that could
potentially be improved using dedicated educational
programs, the involvement of psychologists/
BLOOD PRESSURE 7
sociologists, and/or the implementation of new detec-
tion tools.
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